Teddi Mellencamp sought weight-loss meds amid stage 4 cancer battle

Teddi Mellencamp, the Real Housewives of Beverly Hills alum, spilled on her podcast that she begged her doctor for GLP-1 weight-loss drugs while battling cancer. She gained weight from steroids but got shut down. Joking about the irony, she quipped about living her best life without the meds.

Hold the phone—Teddi Mellencamp just served some real talk on her 'Two Ts In A Pod' podcast. 😲 The reality star admitted she asked her doc for GLP-1s after steroids packed on the pounds during her Stage 4 melanoma fight. But nope, doctor said no dice, leaving her hilariously frustrated: 'You tell me to live my best life ... but where are my GLP-1s?' 👀

관련 기사

Realistic illustration contrasting social stigma: neutral for overweight, positive for exercise weight loss, negative for Ozempic users.
AI에 의해 생성된 이미지

Study finds people who use Ozempic-like drugs for weight loss face added stigma

AI에 의해 보고됨 AI에 의해 생성된 이미지 사실 확인됨

People who lose weight using GLP-1 medications such as Ozempic and Wegovy may be judged more negatively than those who lose weight through diet and exercise — and even more negatively than people who do not lose weight at all — according to a new study led by Rice University psychologist Erin Standen.

Women taking GLP-1 medications such as Ozempic and Wegovy showed about 30 percent lower odds of developing breast cancer in a large observational study.

AI에 의해 보고됨

Scientists have developed a hybrid obesity treatment that uses GLP-1 and GIP signals to deliver a metabolic enhancer directly into cells. Early tests in mice showed greater weight loss and better blood sugar control than standard therapies. The approach aims to reduce side effects by limiting the drug's action to targeted areas.

Katie Thurston received good news in her stage 4 breast cancer battle. Doctors found no evidence of disease in her liver. The Bachelorette star shared the update on her Boobie Broadcast channel.

AI에 의해 보고됨 사실 확인됨

A year-long observational study in Japan suggests that people with type 2 diabetes who tend to overeat in response to tempting food cues such as sight and smell may see greater weight loss—and possibly better blood-sugar improvement—after starting GLP-1 receptor agonists, while those with primarily emotional eating patterns show less consistent links to long-term outcomes.

이 웹사이트는 쿠키를 사용합니다

사이트를 개선하기 위해 분석을 위한 쿠키를 사용합니다. 자세한 내용은 개인정보 보호 정책을 읽으세요.
거부